Cross-talk between HER2 and MED1 regulates tamoxifen resistance of human breast cancer cells.
about
An Experimental Analysis of the Molecular Effects of Trastuzumab (Herceptin) and Fulvestrant (Falsodex), as Single Agents or in Combination, on Human HR+/HER2+ Breast Cancer Cell Lines and Mouse Tumor XenograftsNon-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNALiquid biopsy: monitoring cancer-genetics in the blood.Silencing MED1 sensitizes breast cancer cells to pure anti-estrogen fulvestrant in vitro and in vivo.Antitumor effects of WNT2B silencing in GLUT1 overexpressing cisplatin resistant head and neck squamous cell carcinoma.MED1 mediates androgen receptor splice variant induced gene expression in the absence of ligandAcquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin aUsing Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module.Network Analysis Shows Novel Molecular Mechanisms of Action for Copper-Based ChemotherapyMechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, miRNAs and genetically based resistance.Long interspersed nuclear element ORF-1 protein promotes proliferation and resistance to chemotherapy in hepatocellular carcinoma.The Med1 subunit of the mediator complex induces liver cell proliferation and is phosphorylated by AMP kinase.The recurrence frequency of breast cancer and its prognostic factors in Iranian patients.Mediator Complex Subunit MED1 Protein Expression Is Decreased during Bladder Cancer Progression.miR-221/222: promising biomarkers for breast cancer.Cell-free circulating tumour DNA as a liquid biopsy in breast cancer.ERK and AKT signaling drive MED1 overexpression in prostate cancer in association with elevated proliferation and tumorigenicity.Long-term remission of hormone receptor-positive/HER2-positive metastatic breast cancer due to combined treatment with everolimus/trastuzumab/exemestane: A case report.MiR-873 regulates ERα transcriptional activity and tamoxifen resistance via targeting CDK3 in breast cancer cells.Differences and homologies of chromosomal alterations within and between breast cancer cell lines: a clustering analysis.Reconstructing cancer drug response networks using multitask learning.Tubulin cofactor A functions as a novel positive regulator of ccRCC progression, invasion and metastasis.HER2-Driven Breast Tumorigenesis Relies upon Interactions of the Estrogen Receptor with Coactivator MED1.Overcoming Tamoxifen Resistance of Human Breast Cancer by Targeted Gene Silencing Using Multifunctional pRNA Nanoparticles.Receptor tyrosine kinases (RTKs) in breast cancer: signaling, therapeutic implications and challenges.The mediator complex in genomic and non-genomic signaling in cancer.SOX9 regulates ERBB signalling in pancreatic cancer development.Chromosome 17 copy number changes in male breast cancer.Crosstalk between ERα and Receptor Tyrosine Kinase Signalling and Implications for the Development of Anti-Endocrine Resistance.
P2860
Q28468447-10FA3FF3-1759-425F-B107-C3F2D30EDA70Q29620083-9AB27614-9459-44F6-9C8A-AE538D2414CEQ34356149-F78A557F-3CB2-405F-B986-E4A421C713C8Q34923304-FF4417A7-1880-4468-BA3F-9AAC7186F869Q34991294-933FB457-169C-45B1-B442-D0335EC636E0Q35238452-62809E7A-0BAC-412B-B017-4B4E86CF41F0Q35676447-A3295574-CDB2-4D88-A7AD-E720DA27EC65Q35982590-CE5D075C-FB91-4A9F-BE6F-C1398D4114C7Q36453015-2171843A-3341-435B-BDE5-761E4DD35ED9Q36589865-63E94A93-C1F8-478E-9199-2799AB154A95Q36637698-A9BA688A-93AB-43CB-86F5-118525336EFDQ37201218-5AA20120-796C-4A3C-916E-D259D0098816Q37668443-FF09E785-ECCE-492E-BFA8-B3AC28207BAFQ37707244-DF748910-081A-492E-8B07-9F0D47934074Q38093079-25D67B37-C1F9-4753-B95E-C8BCF50AAFCCQ38699764-65196645-D0EF-40A7-AAC9-1939964EDE7AQ39173954-C2555AD0-259B-44B1-A90E-5A1C0CF26B48Q41142443-8CE8E318-3DC9-4D0C-BAD4-4A3DBFB62F80Q41660033-761215A2-E3EC-4E29-B39B-313FAD35D30EQ41916780-AF9BBA62-A73B-474B-9080-98E2C42D3857Q42374512-9752D056-26AF-4FD1-95FF-36AF0AAF6BA4Q43640552-257F8645-2179-4EAB-8A35-F94B99BEA632Q47350717-7F866924-5A6E-49C5-9F3C-5BA9DCEC5D1BQ48156973-09DC743D-5752-4E5A-B5ED-6D86388AE7C2Q49887925-8B67C885-31A0-4A0B-98D3-1326D0F56727Q52430211-D9C1219A-D34D-4755-8FA6-DE1FC0512282Q53229089-D3708F2C-716F-4D64-89D8-1F0399F43E6CQ54165077-56DE1E86-9547-4977-AEB3-DDBB42209093Q55496875-14573E25-DC67-4BB3-838C-A0C98B46259E
P2860
Cross-talk between HER2 and MED1 regulates tamoxifen resistance of human breast cancer cells.
description
2012 nî lūn-bûn
@nan
2012 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
name
Cross-talk between HER2 and ME ...... of human breast cancer cells.
@ast
Cross-talk between HER2 and ME ...... of human breast cancer cells.
@en
Cross-talk between HER2 and ME ...... of human breast cancer cells.
@nl
type
label
Cross-talk between HER2 and ME ...... of human breast cancer cells.
@ast
Cross-talk between HER2 and ME ...... of human breast cancer cells.
@en
Cross-talk between HER2 and ME ...... of human breast cancer cells.
@nl
prefLabel
Cross-talk between HER2 and ME ...... of human breast cancer cells.
@ast
Cross-talk between HER2 and ME ...... of human breast cancer cells.
@en
Cross-talk between HER2 and ME ...... of human breast cancer cells.
@nl
P2093
P2860
P1433
P1476
Cross-talk between HER2 and ME ...... of human breast cancer cells.
@en
P2093
Jiajun Cui
Jiang Wang
Katherine Germer
Qianben Wang
Shao-chun Wang
Tianying Wu
Xiaoting Zhang
P2860
P304
P356
10.1158/0008-5472.CAN-12-1305
P407
P577
2012-09-10T00:00:00Z